“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
The NDDD team has developed a pipeline of highly differentiated and innovative new chemical entities in focused therapeutic areas of Oncology, Immunology and Metabolic Disorders.
Endocrine:
The clinical Phase-I study successfully completed in Europe and the product was found to be safe and well tolerated. Phase-II study has been initiated in India in chronic kidney disease patients on dialysis and also not-on-dialysis.
Oncology:
Clinical Phase-I study has been successfully completed in Europe on terminally-ill patients (Lung Cancer, Melanoma & Colon Cancer). Phase-II study has commenced in India for treating a refractory type of Lung cancer which has RAS mutations for which no treatment exists worldwide.
In 2019 Lupin and Boehringer Ingelheim announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin’s lead MEK inhibitor compound in combination with one of Boehringer Ingelheim’s innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.
